By VC News Daily
SOUTH SAN FRANCISCO, CA, Circle Pharma today announced the successful closing of a $90 million Series D financing round.
Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note. The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital.
Circle Pharma is advancing the discovery and development of intrinsically cell-permeable macrocycles that multiple routes, including oral administration can deliver. Circle Pharma’s MXMO platform combines structure-based rational drug design and advanced synthetic chemistry to develop a new generation of macrocycle therapies for challenging targets to address unmet clinical needs. Circle Pharma is focusing its development efforts on cyclins, which are master regulators of the machinery that controls the progression of cells through the cell cycle and are key drivers in many cancers.
(c) by Massinvestor, Inc. For contact info, please check out our about page.